ZIVO Bioscience (ZIVO) Competitors

ZIVO Bioscience (NASDAQ:ZIVO) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, community ranking, earnings, risk, valuation and profitability.

Do analysts recommend ZIVO or GOSS?

Gossamer Bio has a consensus target price of $7.75, suggesting a potential upside of 595.07%. Given Gossamer Bio's stronger consensus rating and higher probable upside, analysts clearly believe Gossamer Bio is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Gossamer Bio	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community prefer ZIVO or GOSS?

Gossamer Bio received 58 more outperform votes than ZIVO Bioscience when rated by MarketBeat users. Likewise, 67.09% of users gave Gossamer Bio an outperform vote while only 60.74% of users gave ZIVO Bioscience an outperform vote.

Company	Underperform	Outperform
ZIVO Bioscience	Outperform Votes 99 60.74%	Underperform Votes 64 39.26%
Gossamer Bio	Outperform Votes 157 67.09%	Underperform Votes 77 32.91%

Do institutionals & insiders have more ownership in ZIVO or GOSS?

12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are owned by institutional investors. 21.5% of ZIVO Bioscience shares are owned by company insiders. Comparatively, 6.7% of Gossamer Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Does the media prefer ZIVO or GOSS?

In the previous week, Gossamer Bio had 4 more articles in the media than ZIVO Bioscience. MarketBeat recorded 5 mentions for Gossamer Bio and 1 mentions for ZIVO Bioscience. ZIVO Bioscience's average media sentiment score of 1.16 beat Gossamer Bio's score of 0.94 indicating that ZIVO Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ZIVO Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gossamer Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is ZIVO or GOSS more profitable?

ZIVO Bioscience's return on equity of 0.00% beat Gossamer Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
Gossamer Bio	N/A	-127.28%	-22.12%

Which has better earnings and valuation, ZIVO or GOSS?

ZIVO Bioscience has higher earnings, but lower revenue than Gossamer Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than ZIVO Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	4,503.43	-$7.78M	-$4.93	-3.80
Gossamer Bio	$124.59M	2.03	-$179.82M	-$0.23	-4.85

Which has more risk and volatility, ZIVO or GOSS?

ZIVO Bioscience has a beta of 0.03, suggesting that its share price is 97% less volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500.

Summary

Gossamer Bio beats ZIVO Bioscience on 12 of the 17 factors compared between the two stocks.